ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 YTD Q3 P&L / Income Statement

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 YTD Q3 P&L / Income Statement

Income statement for 2025-10-01 through 2026-06-30. View: Counterparty Name. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

413,023,000 US dollars

Total operating expenses

683,567,000 US dollars

Operating (loss) income

negative 270,544,000 US dollars

Total other (expense) income

negative 17,659,000 US dollars

(Loss) income before income tax expense (benefit) and noncontrolling interest

negative 288,203,000 US dollars

Income tax expense (benefit)

46,000 US dollars

Net (loss) income including noncontrolling interest

negative 288,249,000 US dollars

Glaxosmithkline Intellectual Property Limited

0 US dollars

Madrigal

25,000,000 US dollars

Novartis

74,945,000 US dollars

Sanofi

11,983,000 US dollars

Sarepta

297,594,000 US dollars

Undisclosed (calculated)

3,501,000 US dollars

Total operating expenses

683,567,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to ARROWHEAD PHARMACEUTICALS, INC.: −$296.21 M; to noncontrolling interests: $7.96 M.